thebench.bio #1 Ecosystem for the Bio-Tech Industry

Funding Daily Summary

Funding Daily Summary: What Happened on October 4, 2026

Ai3Bio emerges with $48 million Series A for immune-resetting therapies

The startup plans to test an antibody-guided mRNA approach, with initial human studies possible next year.

  • Updated
  • Read from 1 article, 1 publication

Today in brief

Ai3Bio disclosed a $48 million Series A to advance its immune-resetting therapy pipeline as it emerged from stealth.1

A targeted approach to immune reset

Founding investors Ziff Capital Partners and UPMC Enterprises led the round, with Cockrell Interests and Tanis Ventures also participating.1 Ai3Bio’s first intended target is overactive Th17 cells, which can contribute to autoimmune disease.1

The proposed therapy uses an antibody aimed at CD161 to direct an mRNA-carrying lipid nanoparticle to target cells and activate the cGAS-STING pathway.1 Scientific co-founder Jonathan Kagan said animal studies showed depletion of inflammatory T cells, including deep depletion in monkey spleens and lymph nodes.1

Kagan said the therapy’s durability has not been demonstrated in people.1 CEO Steven Altschuler said initial clinical studies could start with autoimmune liver diseases, and estimated the financing would last through the second quarter of 2027.1